The in vitro activities of moxifloxacin, ciprofloxacin, levofloxacin, gatifloxacin, imipenem, piperacillintazobactam, clindamycin, and metronidazole against 900 surgical isolates were determined using NCCLS testing methods. Moxifloxacin exhibited good to excellent antimicrobial activity against most aerobic (90.8%) and anaerobic (97.1%) microorganisms, suggesting that it may be effective for the treatment of polymicrobial surgical infections.
Infections of the abdominal-pelvic vaults and diabetic limbs involve a mixed microbial flora, often characterized by a high level of antimicrobial resistance (5) (6) (7) . In addition to appropriate antimicrobial spectrum, the ideal antimicrobial agent must also have extensive tissue distribution, as many surgical infections occur in sites where there is significant disruption of tissue plains and vascular supply (7, 17, 22) . Since the introduction of ciprofloxacin in the late 1980s, the fluoroquinolones have been viewed as potent antimicrobials for the treatment of serious gram-negative infections. Newer quinolones have improved in vitro activity against anaerobes, with trovafloxacin, moxifloxacin, and gatifloxacin having more potent activities than levofloxacin and ciprofloxacin (1, 3) . Unfortunately, safety and toxicity concerns have limited the potential therapeutic usefulness of many of these agents (11, 14, 15, 21) . The present study was undertaken to investigate the in vitro activity of moxifloxacin against aerobic and anaerobic clinical isolates recently obtained from surgical patients with diabetic foot and intra-abdominal infections.
Nine hundred sequential, nonduplicated clinical isolates (350 aerobic and 550 anaerobic strains) were collected over a 3-year period (1999 to 2002) from patients with intra-abdominal and diabetic foot infections in a tertiary care medical center in Milwaukee, Wis. (three surgical services: vascular surgery, trauma and critical care, and pancreatobiliary surgery). NCCLS-recommended reference broth and agar dilution methods were used for aerobic and anaerobic susceptibility testing, respectively (18, 19) . Microbroth and agar dilution plates were prepared on the day of testing and incubated at 35°C for 24 h (aerobes) and 48 h (anaerobes), respectively. Gram-positive and gram-negative aerobic-facultative isolates were tested in Mueller-Hinton broth. Anaerobic strains were tested within an anaerobic chamber on brucella blood agar plates supplemented with 5 g of hemin, 1 g of vitamin K 1 per ml, and 5% lysed sheep blood. The agar dilution plates were inoculated (10 5 Citrobacter spp. and Enterobacter spp., the percent susceptibility to piperacillin-tazobactam was highly variable (range, 70 to 83.3%). Overall, 90.8% of aerobic gram-positive and gramnegative surgical isolates were susceptible to moxifloxacin.
Among the 550 gram-positive and gram-negative anaerobes tested, Bacteroides was the most common genus (n ϭ 310), The following MICs were used as susceptibility breakpoints as recommended by the NCCLS (18): ciprofloxacin, Յ1 mg/liter; moxifloxacin, Յ2 mg/liter (Staphylococcus spp.) and Յ1 mg/liter (Streptococcus spp.) (note: no NCCLS breakpoints have been established for moxifloxacin against Enterobacteriaceae); gatifloxacin, Յ2 mg/liter (Staphylococcus spp.) and Յ1 mg/liter (Streptococcus spp.); levofloxacin, Յ2 mg/liter; piperacillin-tazobactam, Յ32 mg/liter (Enterobacteriaceae) and Յ8 mg/liter (Staphylococcus spp.); and imipenem, Յ4 mg/liter. b S. pyogenes (10), S. agalactiae (10), S. viridans (10) . Actinomyces spp. Moxifloxacin demonstrates broad-spectrum in vitro activity against both gram-positive and gram-negative aerobic and anaerobic surgical isolates compared to other anti-infectives commonly used in the treatment of surgical infections. Empirical therapy of mixed, aerobic, and anaerobic infections remains challenging because of the rising resistance rates of surgical pathogens, such as E. coli and B. fragilis. Data collected from 1987 to 1999 revealed that 22% of B. fragilis isolates from bloodstream infections were resistant to clindamycin (2) . In the same surveillance study, however, Ն96% of B. fragilis strains were susceptible to imipenem, metronidazole, and trovafloxacin (the only quinolone tested). Inappropriate therapy for serious anaerobic infections (e.g., bacteremic complications of peritonitis) has been associated with at least a twofold-increased mortality rate (16, 20) as well as significantly increased rates of clinical and bacteriologic failure (20) .
Enterobacter aerogenes
In the present study, moxifloxacin demonstrated good to excellent activity against over 19 species of anaerobic bacteria. These data support the results of previous studies that found moxifloxacin to be highly active against clinical isolates of B. fragilis (4, 10, 13) . However, a recent in vitro study has suggested that quinolone resistance among members of the B. fragilis group may be increasing, possibly limiting the therapeutic utility of selective agents (23) . It should be noted that the NCCLS has not yet adopted a susceptibility breakpoint for moxifloxacin against the B. fragilis group, and therapeutic speculation relative to interpretation of in vitro susceptibility data is at best preliminary. Not unexpectedly, many B. fragilis isolates were nonsusceptible to clindamycin based on an MIC 90 of 4 mg/liter (NCCLS-recommended susceptible breakpoint is Յ2 mg/liter). This high degree of resistance to clindamycin confirms the findings of at least one other recent report wherein only 78% of B. fragilis isolates were susceptible to clindamycin (2) . Moxifloxacin also demonstrated good to excellent in vitro activity against Clostridium spp. and Fusobac- (2), C. innocuum (7) , C. ramosum (7) , C. sporogenes (1), C. subterminale (6) , C. tertium (2), C. tyrobutyricum (1) . e F. varium (2), F. necrophorum (7) , F. russii (1). f P. asaccharolytica (5) , P. gingivalis (5) . g P. buccae (5) , P. denticola (5) , P. intermedia (5) , P. disiens (5) , P. bivia (5) , P. melaninogenicus (5) . on June 26, 2017 by guest http://aac.asm.org/ terium spp. isolates from infections involving the peritoneal cavity. In addition, all anaerobic streptococcal isolates from diabetic foot and intra-abdominal infections were susceptible to moxifloxacin. Selection of an effective antimicrobial agent for a surgical infection requires knowledge of the potential microbial pathogens, an understanding of the pathophysiology of the infectious process, and an understanding of the pharmacology and pharmacokinetics of the intended therapeutic agent (7, 8) . Quinolones have been effective in the treatment of selected surgical infections in part because of their excellent activity against aerobic gram-negative bacteria and tissue penetration (9) . However, the extended-spectrum and broad-spectrum quinolones do not exhibit potent antianaerobic activity and as such must be used in combination with other therapeutic (antianaerobic) agents. The present study suggests that moxifloxacin exhibits potent activity against both aerobes and anaerobes and may be an effective agent for the treatment of both community-or hospital-acquired intra-abdominal infection and diabetic foot infection, both of which involve a complexed polymicrobial flora (12, 17, 22) .
